Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Rectal misoprostol versus intravenous oxytocin for the prevention of postpartum hemorrhage after vaginal delivery

Article Abstract:

A rectal suppository containing misoprostol was less effective than intravenous oxytocin in preventing postpartum hemorrhage in a study of 325 women. Oral misoprostol may be preferable, since it is cheap, easy to take, and can be stored at room temperature.

Author: Wing, Deborah A., Gerstenfeld, Tammy S.
Publisher: Elsevier B.V.
Publication Name: American Journal of Obstetrics and Gynecology
Subject: Health
ISSN: 0002-9378
Year: 2001
Prevention, Hemorrhage, Rectum, Medication by, Rectal medication

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


A comparison of misoprostol and prostaglandin E2 gel for preinduction cervical ripening and labor induction

Article Abstract:

The drug misoprostol may be effective at ripening the cervix in preparation for induction of labor, but the dosage is in question. Researchers compared the effectiveness of vaginally administered misoprostol (prostaglandin E1) to that of dinoprostone (prostaglandin E2) gel applied to the cervix for cervical ripening before induction of labor. More patients receiving misoprostol required oxytocin to induce labor less often, had riper cervices before induction of labor, and were able to deliver vaginally within 24 hours of induction. Undesirable side effects of misoprostol were a rapid rate of uterine contractions and meconium in the amniotic fluid. The dosage of misoprostol was 50 microgram tablets every three hours for up to six doses.

Author: Goodwin, T. Murphy, Wing, Deborah A., Paul, Richard H., Jones, Margaret M., Rahall, Ann
Publisher: Elsevier B.V.
Publication Name: American Journal of Obstetrics and Gynecology
Subject: Health
ISSN: 0002-9378
Year: 1995
Physiological aspects, Cervix uteri, Prostaglandins E, Incompetent cervix

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


A comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction

Article Abstract:

A medicated tablet called Cytotec that contains misoprostol and is placed on the cervix appears to be equally effective in reducing a woman's time in labor as a medicated, time-released vaginal suppository called Cervidil that contains dinoprostone. Ninety-nine women were treated with Cytotec and 101 women were treated with Cervidil to induce labor. Women given Cytotec delivered an average of one hour earlier and were less likely to experience rapid contractions but were slightly more likely to need oxytocin than those given Cervidil. An equal number of women in each group ultimately delivered by cesarean.

Author: Wing, Deborah A., Paul, Richard H., Ortiz-Omphroy, Gabriela
Publisher: Elsevier B.V.
Publication Name: American Journal of Obstetrics and Gynecology
Subject: Health
ISSN: 0002-9378
Year: 1997
Methods, Vagina, Medication by, Vaginal medication, Synthetic prostaglandins E

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Evaluation, Misoprostol, Labor, Induced (Obstetrics), Induced labor
Similar abstracts:
  • Abstracts: Mifepristone versus vaginally administered misoprostol for cervical priming before first-trimester termination of pregnancy: a randomized, controlled study
  • Abstracts: A prospective, randomized comparison of Foley catheter insertion versus intracervical prostaglandin E(sub)2 gel for preinduction cervical ripening
  • Abstracts: The frequency and clinical significance of intra-amniotic inflammation in patients with a positive cervical fetal fibronectin
  • Abstracts: Assessing care of vulnerable elders: methods for developing quality indicators. Assessing care of vulnerable elders: ACOVE project overview
  • Abstracts: Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. Association Between Myeloperoxidase Levels and Risk of Coronary Artery Disease
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.